drugset / Trial / NCT00610649

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

NCT00610649 ↗

Phase 2 Completed 54 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.

Timeline

Start
2007-09-20
Primary completion
2008-11-18
Completion
2008-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8777 Unknown 100 mg Oral
Subject MK-8777 Unknown 400 mg Oral
Subject MK-8777 Unknown 600 mg Oral

Indications